Management of hepatitis B in liver transplant recipients

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 37-44

  Coffin, Carla S ^b,c   Terrault, Norah A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adefovir; Entecavir; Hepatitis B immune globulin; Lamivudine; Prophylaxis; Tenofovir

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INDIVIDUALIZATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS MUTANT;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; LIVER TRANSPLANTATION;

EID: 35448982768     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00916.x     Document Type: Conference Paper

References (57)

1. Vierling J, Teperman L. Introduction to hepatitis B transplantation. Semin Liver Dis 2000 1: 1 2.
2. Buti M, Antonio M, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003 38 (6 811 817.
3. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000 32 (6 1189 1195.
4. Brind A, Jiang J, Samuel D et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997 26 (2 228 235.
5. Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990 49 (6 1155 1158.
6. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, Denis F, Alain S. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods 2006 138 (1-2 70 79.
7. Allen M, Deslauriers M, Andrews C et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998 27: 1670 1677.
8. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001 8 (3 237 247.
9. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001 33 (3 751 757.
10. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 329 (25 1842 1847.
11. Marzano A, Lampertico P, Mazzaferro V et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005 11 (5 532 538.
12. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 11 (4 402 409.
13. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006 12 (2 253 258.
14. Schiff E, Lai C, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38: 1419 1427.
15. Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 2000 69 (11 2382 2383.
16. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001 34 (2 411 416.
17. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 (6 1414 1419.
18. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 354 (10 1001 1010.
19. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 354 (10 1011 1020.
20. Van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004 40 (6 1421 1425.
21. Van Bommel F, Zollner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006 44 (2 318 325.
22. Lai C-L, Gane E, Liaw Y-F et al. Telbivudine vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial. Hepatology 2005 42 (4 77A (Late Breaking Abstract #1).
23. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 (2 528 536.
24. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006 44 (2 283 290.
25. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007 51 (3 902 911.
26. Kanwal F, Farid M, Martin P et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006 101 (9 2076 2089.
27. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004 10 (8 968 974.
28. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005 11 (7 716 732.
29. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002 8 (10 Suppl. 1 S67 S73.
30. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998 28 (2 585 589.
31. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003 3 (8 999 1002.
32. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001 34 (6 903 910.
33. Zhu JP, Zhang TL, Li L et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2003 2 (4 500 503.
34. Taltavull TC, Chahri N, Verdura B et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int 2005 18 (7 879 883.
35. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004 77 (8 1203 1208.
36. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 132 (3 931 937.
37. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 6 (4 429 433.
38. Dickson RC, Terrault NA, Ishitani M et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006 12 (1 124 133.
39. Wong SN, Chu CJ, Wai CT et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007 13 (3 374 381.
40. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 61 (9 1358 1364.
41. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000 6 (6 741 748.
42. Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002 235 (5 611 619 (discussion 619-620).
43. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999 5 (6 491 496.
44. Buti M, Antonio M, Prieto M et al. Five year follow-up of a randomized study comparing lamivudine vs. lamivudine + HBIG in the prevention of HBV recurrence after liver transplantation, abstract no. 750 in 56th Annual AASLD Conference. Hepatology 2005 42 (S1 491A.
45. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 (2 424 432.
46. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003 38 (1 86 95.
47. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 24 (6 1327 1333.
48. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38 (6 1419 1427.
49. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 (1 81 90.
50. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res 2007 37 (S1 S67 S78.
51. Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology 2007 132 (4 1586 1594.
52. Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007 13 (3 323 326.
53. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46 (1 254 265.
54. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 (2 507 539.
55. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002 35 (6 1528 1535.
56. Yan ML, Yan LN, Li B et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2006 5 (3 360 363.
57. Neff GW, O'Brien CB, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004 10: 1372 1378.